High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome

Tao Hong, Jiao-Yang Li, Ya-Di Wang, Xiao-Yan Qi, Zhe-Zhen Liao, Poonam Bhadel, Li Ran, Jing Yang, Bin Yan, Jiang-Hua Liu, Xin-Hua Xiao, Tao Hong, Jiao-Yang Li, Ya-Di Wang, Xiao-Yan Qi, Zhe-Zhen Liao, Poonam Bhadel, Li Ran, Jing Yang, Bin Yan, Jiang-Hua Liu, Xin-Hua Xiao

Abstract

Objective: Asprosin, a new adipocytokine, has reportedly been associated with glucose release, dyslipidemia, and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aimed to investigate serum asprosin levels in MetS as well as their association with various metabolic parameters in humans.

Methods: A total of 131 consecutive patients with MetS, and 162 age-matched, healthy subjects were recruited for this study. Serum asprosin concentrations were determined using the enzyme-linked immunosorbent assay. Lipid profile, glucose, insulin, and inflammatory markers were also measured.

Results: Serum asprosin levels were higher in subjects with MetS (23.52 [16.70, 32.05] ng/mL) than in controls (16.70 [12.87, 22.38] ng/mL; P < 0.01), and they showed an increasing trend with increasing numbers of metabolic components (P for trend < 0.01). In all studied subjects, serum asprosin levels were positively correlated with body mass index, waist circumference, triglycerides, fasting plasma glucose, 2-hour plasma glucose, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR) index, interleukin-6, and monocyte chemoattractant protein-1 and negatively correlated with high-density lipoprotein cholesterol (P < 0.05). In multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR (P < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR, even after controlling for anthropometric variables, lipid profiles, and inflammatory markers.

Conclusion: Asprosin is a potential metabolic-related adipokine and may be related to IR and MetS. This trial was registered with ChiCTR, ChiCTR1800018347.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Copyright © 2021 Tao Hong et al.

Figures

Figure 1
Figure 1
Serum asprosin levels in the study population. (a) Distribution of serum asprosin levels in 162 control subjects; (b) distribution of serum asprosin levels in 131 MetS subjects; (c) serum asprosin levels in control and MetS subjects; values were provided as median with interquartile range and log-transformed before analysis; (d) serum asprosin levels in the whole study population according to waist circumference (nonobesity: waist circumference 25.79 ng/mL (Q: quartile).
Figure 2
Figure 2
ROC curve analyses ROC curve analyses were performed for the prediction of serum asprosin for 16 MetS (a) and IR (b). MetS, metabolic syndrome; IR, insulin resistance.

References

    1. Alberti K. G. M. M., Eckel R. H., Grundy S. M., et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–1645. doi: 10.1161/circulationaha.109.192644.
    1. Mottillo S., Filion K. B., Genest J., et al. The metabolic syndrome and cardiovascular risk. Journal of the American College of Cardiology. 2010;56(14):1113–1132. doi: 10.1016/j.jacc.2010.05.034.
    1. O’Neill S., O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews. 2015;16(1):1–12. doi: 10.1111/obr.12229.
    1. Pucci G., Alcidi R., Tap L., Battista F., Mattace-Raso F., Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacological Research. 2017;120:34–42. doi: 10.1016/j.phrs.2017.03.008.
    1. Lindberg S., Jensen J. S., Bjerre M., et al. Low adiponectin levels at baseline and decreasing adiponectin levels over 10 years of follow-up predict risk of the metabolic syndrome. Diabetes & Metabolism. 2017;43(2):134–139. doi: 10.1016/j.diabet.2016.07.027.
    1. Lei L., Li K., Li L., et al. Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin. Nutrition & Metabolism. 2017;14:p. 53. doi: 10.1186/s12986-017-0210-6.
    1. Abu-Farha M., Abubaker J., Al-Khairi I., et al. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovascular Diabetology. 2016;15:p. 25. doi: 10.1186/s12933-016-0346-0.
    1. Romere C., Duerrschmid C., Bournat J., et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–579. doi: 10.1016/j.cell.2016.02.063.
    1. Jung T. W., Kim H. C., Kim H. U., et al. Asprosin attenuates insulin signaling pathway through PKCδ‐activated ER stress and inflammation in skeletal muscle. Journal of Cellular Physiology. 2019;234(11):20888–20899. doi: 10.1002/jcp.28694.
    1. Lee T., Yun S., Jeong J. H., Jung T. W. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Molecular and Cellular Endocrinology. 2019;486:96–104. doi: 10.1016/j.mce.2019.03.001.
    1. Wang C.-Y., Lin T.-A., Liu K.-H., et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. International Journal of Obesity. 2019;43(5):1019–1025. doi: 10.1038/s41366-018-0248-1.
    1. Ugur K., Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. International Journal of Endocrinology. 2019;2019:8. doi: 10.1155/2019/2521096.2521096
    1. Wang Y., Qu H., Xiong X., et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation. 2018;2018:7. doi: 10.1155/2018/9471583.9471583
    1. Zhang L., Chen C., Zhou N., Fu Y., Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica Acta. 2019;489:183–188. doi: 10.1016/j.cca.2017.10.034.
    1. Naiemian S., Naeemipour M., Zarei M., et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetology & Metabolic Syndrome. 2020;12:p. 65. doi: 10.1186/s13098-020-00564-w.
    1. Zhang X., Jiang H., Ma X., Wu H. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2020;11(2):349–355. doi: 10.1111/jdi.13148.
    1. Duerrschmid C., He Y., Wang C., et al. Asprosin is a centrally acting orexigenic hormone. Nature Medicine. 2017;23(12):1444–1453. doi: 10.1038/nm.4432.
    1. Long W., Xie X., Du C., et al. Decreased circulating levels of asprosin in obese children. Hormone Research in Paediatrics. 2019;91(4):271–277. doi: 10.1159/000500523.
    1. Alan M., Gurlek B., Yilmaz A., et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology. 2019;35(3):220–223. doi: 10.1080/09513590.2018.1512967.
    1. Li X., Liao M., Shen R., et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators of Inflammation. 2018;2018:12. doi: 10.1155/2018/7375294.7375294
    1. Sünnetçi Silistre E., Hatipoğl H. U. Increased serum circulating asprosin levels in children with obesity. Pediatrics International. 2020;62(4):467–476. doi: 10.1111/ped.14176.
    1. Wang M., Yin C., Wang L., et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Annals of Nutrition and Metabolism. 2019;75(4):205–212. doi: 10.1159/000503808.
    1. Chang C. L., Huang S. Y., Hsu Y. C., Chin T. H., Soong Y. K. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Scientific Reports. 2019;9:p. 6447. doi: 10.1038/s41598-019-42061-9.
    1. Li J.-Y., Wang Y.-D., Qi X.-Y., et al. Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation. Clinica Chimica Acta. 2019;494:52–57. doi: 10.1016/j.cca.2019.03.006.
    1. Park S. E., Park C.-Y., Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Critical Reviews in Clinical Laboratory Sciences. 2015;52(4):180–190. doi: 10.3109/10408363.2015.1023429.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere